NixonR, PickupJC. Fear of hypoglycemia in type 1 diabetes managed by continuous subcutaneous insulin infusion: is it associated with poor glycemic control?. Diabet Technol Ther, 2011; 13: 93–98.
HellerS, WhiteD, LeeE, LawtonJ, PollardD, WaughN, AmielS, BarnardK, BeckwithA, BrennanA, CampbellM, CooperC, DimairoM, DixonS, ElliottJ, EvansM, GreenF, HackneyG, HammondP, HallowellN, JaapA, KennonB, KirkhamJ, LindsayR, MansellP, PapaioannouD, RankinD, RoyleP, SmithsonWH, TaylorC. A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial. Health Technol Assess, 2017; 21: 20.
5.
BeckRW, RiddlesworthT, RuedyK, AhmannA, BergenstalR, HallerS, KollmanC, KrugerD, McGillJB, PolonskyW, ToschiE, WolpertH, PriceD; DIAMOND Study Group. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA, 2017; 317: 371–378.
6.
LindM, PolonskyW, HirschIB, HeiseT, BolinderJ, DahlqvistS, SchwarzE, ÓlafsdóttirAF, FridA, WedelH, AhlénE, NyströmT, HellmanJ. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA, 2017; 317: 379–387.
7.
HeiseT, ZijlstraE, NosekL, RikteT, HaahrH. Pharmacological properties of faster-acting insulin aspart vs. insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: a randomized, double-blind, crossover trial. Diabetes Obes Metab, 2017; 19: 208–215.
8.
RossP, GrayAR, MilburnJ, KumarasamyIM, WuF, FerrandS, ArmishawJ, WiltshireE, RaynsJ, TomlinsonP, WheelerBJ. Insulin pump-associated adverse events are common, but not associated with glycemic control, socio-economic status, or pump/infusion set type. Acta Diabetol, 2016; 53: 991–998.
9.
PickupJC, YemaneN, BrackenridgeA, PenderS. Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey. Diabetes Technol Ther, 2014; 16: 145–149.
